CANBERRA: A Phase II Randomized Clinical Trial to Test the Therapeutic Potential of Oral Vicasinabin in Diabetic Retinopathy.

ABSTRACT:

Objective

Nonproliferative diabetic retinopathy (NPDR) is a progressive disease that can lead to blindness. Current therapies for NPDR are invasive and not extensively used or accessible until the disease progresses, pointing to the need for an early noninvasive treatment. The objective of CANBERRA was to assess the safety, tolerability, and efficacy of oral administration of vicasinabin (RG7774) on the severity of diabetic retinopathy (DR) in participants with moderately severe to severe NPDR and good vision.

Design

CANBERRA was a global, multicentric randomized, double-masked, parallel-group, placebo-controlled, phase II study. The study duration was 36 months.

Participants

A total of 139 treatment-naïve patients with type 1 or type 2 diabetes mellitus and Diabetic

SUBMITTER: Armendariz BG 

PROVIDER: S-EPMC11719906 | biostudies-literature | 2025 Mar-Apr

REPOSITORIES: biostudies-literature